S100A9 and melanoma: Here, we expand upon this concept and demonstrate that multivalent display of S100A9‐targeting ligands directs the CPMV nanoparticles to the lung TME and induces treatment as evident by reduced tumor burden in the lungs after mice were i.v. challenged using melanoma cells or TNBCs (Figure 4).